Sarepta Therapeutics Annual Income Statement (NASDAQ:SRPT)

Add to My Stocks
$36.13 $1.7 (4.49%) SRPT stock closing price Jan 17, 2017 (Closing)

Looking at financial statements, along with the Sarepta Therapeutics stock price, it's management, its economic moat, and industry competitors forms an important part of fundamental analysis.   In the income statement, an investor can look at important parameters like revenue, gross profits, net profits, and EPS basic to gain deeper insights. The income statement is generated for a specific period of time. The revenue decrease of $1.25M for 2015 impacts the SRPT stock. Investors typically check year over year or quarter over quarter revenue growth. The Sarepta Therapeutics profit and loss statement for 2015 shows a profit of $-220.03M. Profits have reduced from $-135.78M YoY. Apart from this an investor should also check Sarepta Therapeutics assets and Sarepta Therapeutics free cash flow. Sarepta Therapeutics revenue for 2015 is $1.25M. View revenue and profit details for latest and last 10 financial years.

show more
Annual
Quarterly
View Previous Years
View Next Years
Fiscal year is Jan - Dec. 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006
Sarepta Therapeutics Net Sales or Revenues
1.25M9.75M14.21M37.32M46.99M29.42M17.58M21.25M10.98M0.11M
Cost Of Goods Sold (COGS)----------
Sarepta Therapeutics Gross Profit
1.25M9.75M14.21M37.32M46.99M29.42M17.58M21.25M10.98M0.11M
Research & Development Expense146.39M94.23M72.9M52.4M66.86M35.97M24.39M38.91M34.76M25.34M
Selling General & Admin Expense75.04M49.31M31.59M14.63M16.05M14.38M8.69M9.79M9.33M7.75M
Income Before Depreciation Depletion Amortization-220.18M-133.78M-90.28M-29.7M-35.92M-20.93M-15.5M-27.45M-33.1M-32.98M
Depreciation Depletion Amortization----------
Non Operating Income0.15M-2M-21.7M-91.58M33.6M-11.24M-9.65M3.5M5.93M1.91M
Interest Expense----------
Sarepta Therapeutics Pretax Income
-220.03M-135.78M-111.98M-121.28M-2.31M-32.17M-25.15M-23.95M-27.16M-31.07M
Provision for Income Taxes----------
Minority Interest----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-220.03M-135.78M-111.98M-121.28M-2.31M-32.17M-25.15M-23.95M-27.16M-31.07M
Extraordinary Items & Discontinued Operations----------
Sarepta Therapeutics Net Income (Profit/Loss)
-220.03M-135.78M-111.98M-121.28M-2.31M-32.17M-25.15M-23.95M-27.16M-31.07M
Average Shares used to compute Diluted EPS42.29M40.03M33.85M23.6M21.6M18.54M15.52M11.58M8.99M8.78M
Average Shares used to compute Basic EPS42.29M40.03M33.85M23.6M21.6M18.54M15.52M11.58M8.99M8.78M
Income Before Nonrecurring Items-220.03M-133M-89.19M-29.35M-2.32M-32.17M-25.16M-23.95M-27.17M-31.07M
Income from Nonrecurring Items--2.79M-22.79M-91.94M------
Sarepta Therapeutics Earnings Per Share Basic Net
-5.20-3.39-3.31-5.14-0.12-1.74-1.62-2.04-3.00-3.54
Sarepta Therapeutics Earnings Per Share Diluted Net
-5.20-3.39-3.31-5.14-0.12-1.74-1.62-2.04-3.00-3.54
EPS Diluted Before Nonrecurring Items-5.20-3.32-2.64-1.24-0.12-1.74-1.62-2.04-3.00-3.54
Preferred Dividends Acc Pd----------
Dividends Common----------
Dividend Per Share Common----------
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years
Get Income statement for another ticker

1:11
SRPT
The key things to look for in an income statement while doing Sarepta Therapeutics stock analysis are:
  • Top line: The word topline comes from the fact that the first line of an income statement refers to sales numbers. If you check you will find that SRPT stock has a topline or revenue of $1.25M for 2015 as per this Sarepta Therapeutics revenue chart. Investors look for stocks with a growing top line.
  • Bottom line: The word bottom line comes because it is usually the last line of the income statement and refers to the actual profits after deducting all expenses from the revenues. SRPT stock had a poor bottom line growth.
The income statement is also called statement of revenue and expense. The financials along with Sarepta Therapeutics historical stock prices provides a lot of details about the firm. .